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Anesthesiologists perceive that the ideal muscle relaxant is not yet available,
particularly the nondepolarizing one with a rapid onset and a short duration of
action. There is also a need for relaxants with different durations of action but
which would be free from side effects. During the process ofthis development
several new compounds have been tested and four have reached an advanced
state of study; three of these, doxacurium, pipecuronium, and mivacurium are
already licensed and rocuronium is likely to be licensed in the near future.
Doxacurium and pipecuronium are slow onset andlong duration ofaction com-
pounds but singularly free from cardiovascular side effects. Mivacurium has an
onset comparable to that of atracurium and vecuronium but with a duration of
action which is intermediate in duration between these drugs and succinyl-
choline. Rocuronium is a drug with a fast onset of action capable ofbeing used
in place ofsuccinylcholine but with a duration ofaction which is similar to that
ofvecuronium.
Nondepolarizing relaxants have been an integral partofanesthetic practice eversince
the introduction of curare in 1942. These agents act predominantly by competing with
Achb for the postsynaptic receptor. Occupation of even only one of the binding sites on
the receptor complex by these agents prevents Ach from opening the ion channel and ini-
tiating theprocess that ultimately leads to musclecontraction. Theblockingdrug does not
remain in contact with the receptors but like Ach keeps on associating and dissociating
from it [1]. The neuromuscular blocking drug does, therefore, not prevent the interaction
ofAch with the receptorbut merely reduces the chances ofitdoing so; this is thebasis of
the reversible block by competition [1]. Nondepolarizing neuromuscular blockers also
exert varying degrees ofeffect on the prejunctional cholinoceptors and this is reflectedby
fade in response to the train-of-four and tetanic stimulations [2]. Only in large doses do
relaxants produce true ion channel block.
New muscle relaxants have been developed and introduced at regular intervals in
order to meet the criteria of an ideal neuromuscular blocking agent. Although an ideal
muscle relaxant has been defined as an agent with non-cumulative, nondepolarizing
action, with rapid onset and recovery, Savarese and Kitz [3] have suggested that clinical
anesthesia needs threedifferent typesofnondepolarizing neuromuscular agents, rapidand
short-acting, intermediate acting and long-acting. These would fill the needs ofdifferent
durations of surgery. Within all three categories of relaxants absence of side effects is a
desirable feature.
The introduction ofpancuronium in 1967 was a major breakthrough in the develop-
ment of neuromuscular blocking agents. This was one of the few agents which was not
associated with any significant histamine liberation or ganglion blockade, thus providing
an agent with significant cardiovascular advantages [4]. Although pancuronium has been
a very popular muscle relaxant since then, it has in common with d-tubocurarine a rela-
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tively slow onset and a long duration ofaction. In addition some consider the cardiovas-
cular stimulating effects ofpancuronium undesirable [5]. The early 1980's saw the intro-
duction of atracurium and vecuronium, the two most commonly used neuromuscular
blocking agents in the UK and probably the rest ofEurope [6]. These, however, fulfilled
only the group described by Savarese and Kitz as "intermediate duration agents." A com-
mon shortcoming ofboth these drugs is thatneither approach the speed ofonset or dura-
tion of action of succinylcholine. Since atracurium and vecuronium have been well
described in the literatureand haveadmirably fulfilled the intermediate duration category
of muscle relaxant these will not be described here any more. Instead, this review will
focus on two longer-acting agents, doxacurium and pipecuronium, and two other agents,
mivacurium and rocuronium, which have been designed in an effort to fulfill the criteria
requiredofa shortduration andfastaction nondepolarizing drug.
Doxacurium chloride
Doxacurium is a bisquaternary benzylisoquinolinium compound which has been
approved for use in the United States since 1991. It is currently the mostpotentnondepo-
larizing neuromuscular blocking agent available with an estimated ED95 of
approximately 30gg/kg [7, 8].
The onset and duration ofaction ofdoxacurium arecharacteristic ofa slow and long-
acting drug. Onset times are very variable and show a lot ofindividual variability. Doses
equal to 1 x ED95 have been reported to produce maximum block in times ranging from 3
to 13 min, with a duration ofclinical relaxation ofbetween 30 min and over 1.5 hrs [8, 9].
The onsetofaction is faster, with less variability and in theregion ofabout4-5 min ifthe
dose is increased to 40-60 jg/kg. However, this is at the expense ofa further increase in
the duration of clinical relaxation [7, 10]. Increasing the dose further to 80 jg/kg results
in a duration ofclinical relaxation ofover2.5 hrs [11]. Becauseofsuch a long duration of
action, it is likely that doxacurium will cumulate although there are no data to support
this because the effect of even a single dose lasts quite a long time. Because ofthe slow
onset of action, doxacurium is not suitable for facilitating intubation within 2-3 min of
administration ofthe drug.
Although antagonism of doxacurium block by neostigmine is satisfactory provided
adequate spontaneous recovery has takenplace, the time taken to achieve adequate antag-
onism is extremely variable and may take more than 20 min, even when greater than 25%
recovery ofthe twitch has taken place [7, 8]. Ifantagonism is attempted at very deep lev-
els ofblock, it is perhaps inadequate and extremely slow. For this reason, it is advocated
that doxacurium block is not antagonised unless considerable spontaneous recovery has
taken place.
The elimination half-life ofdoxacurium has been reported to vary between 86 and 99
min, but this is considerably prolonged in patients with renal failure [12, 13]. The same
authors have described the rate ofclearance to be between 0.13 and 0.161Ag/hr and the
volume of distribution of 0.15-0.22 L/kg in adult subjects with a dose of 25 jg/kg. The
volumeofdistribution may be increased in the elderly and in those with hepatic and renal
failure. Patients with renal failure show a markedly increased mean residence time, but
those with liver failure show only moderate increase both in the mean residence time as
well as the duration ofaction. The increased duration ofaction ofdoxacurium in patients
with renal failure has been confirmed in a study reported by Cashman etal. [14].
A singular property of doxacurium chloride is the lack of any significant cardiovas-
cular effects. In fact, it appears that this is the only advantage ofthis drug in clinical use.
This has been confirmed by detailed hemodynamic studies which have shown no signifi-
cant changes in mean arterial pressure or cardiac index with doxacurium, in contrast to a
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significant increase in these parameters following pancuronium and a small, but signifi-
cant decrease following vecuronium [15, 16]. There may, however, be some reduction in
heart rate which, though statistically significant, is of little clinical consequence.
Doxacurium is generally free from causing any increase in plasma histamine levels,
although a case with transient systemic arterial hypotension and cutaneous flushing has
been reported [17].
The commonly used doses ofdoxacurium range from 25 to 50 jg/kg.
Pipecuronium bromide
Pipecuronium bromide, in contrast to doxacurium chloride, is a bisquaternary
steroidal neuromuscular blocking agent originally used in Hungary [18]. In recent years,
the drug has been investigated in the Western world and recently introduced in the USA.
The potency of pipecuronium in terms of its ED95 is approximately 45 jig/kg using
mechanomyography, although the ED95 has been reported to be somewhat higher atjust
under 60 jg/kg using electromyography [19,201.
The neuromuscular blocking effects of pipecuronium are dose-dependent, higher
doses leading to shorter onset times and longer durations of action. A dose of 45 to 50
gg/kg produces maximum block in 3.5 to 5 min and has a duration ofclinical relaxation
of approximately 40 min [20-22]. The onset of block is significantly shorter at 2 to 2.5
min following a dose ofapproximately 2 xED95, but with a duration ofclinical relaxation
which is close to 2 hrs [22, 24]. Although similar durations of effect have been reported
with up to three repeat doses of the agent, it is likely that the drug will cumulate over a
period of time once given in repeated doses. It is difficult, as with doxacurium, to deter-
mine the cumulative potential ofa very long-acting drug. Pipecuronium, like doxacurium,
is not suitable for situations where intubation needs to be carried outrapidly although the
conditions have been described as good or excellent at 3 min following a dose of 70
jg/kg [24].
The antagonism of neuromuscular block with neostigmine can be carried out satis-
factorily as long as there is spontaneous recovery in excess of20% or so [25]. The recov-
ery occurs at a relatively slow speed and adequate antagonism may take more than 10
min., particularly if anesthesia has been maintained with isoflurane [26]. Edrophonium
appears to be an unreliable and ineffective antagonist [25]. The neuromuscular effects of
pipecuronium, therefore, do notprovide any advantage overagents like pancuronium.
Like doxacurium, the main virtue ofpipecuronium appears to be cardiovascular sta-
bility. In acomparative study ofpancuronium andpipecuronium, there was an increase of
22% in heart rate and significant increases in mean arterial pressure, cardiac index, and
rate-pressure product following administration ofpancuronium, whereas these parameters
showed very little change following the administration of pipecuronium in patients
undergoing coronary artery surgery [27]. Cardiovascular stability is generally maintained
even with doses as high as 200gg/kg, although there may be some reduction in cardiac
output [28].
As with doxacurium, the elimination half-life of pipecuronium is in the region of 2
hrs and is almost doubled in patients with significant renal failure [29]. The steady-state
volume of distribution is similar to that of doxacurium at about 300 mL/kg increasing
somewhat in patients with renal failure. The clearance is reduced in patients with renal
dysfunction [29]. Although this increase in elimination half-life and reduced clearance
was not associated with a significant increase in duration of clinical relaxation in the
study ofCaldwell et al., the patients with renal dysfunction showed extremely large inter-
patient variability. The effects of pipecuronium may also be prolonged in patients with
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significant hepatic disease.
In conclusion, therefore, pipecuronium, like doxacurium, appears to be an agent
which resembles pancuronium in its neuromuscular effects. The main advantage of this
drug is in its cardiovascular stability which mightbe an advantage in patients with cardio-
vascular disease undergoingprolonged surgery. The usual clinical dose is 50-80jg/kg.
Mivacuriun chloride
This agent is a bisquaternary benzylisoquinolinium compound which resembles
atracurium in its structure. The drug has beenrecently released for use in theUS, the UK,
and parts ofEurope.
The ED95 ofmivacurium has been shown to vary between 60 and 80jig/kg depend-
ing upon the anesthetic technique used and the method ofstimulation applied [30-32]. As
with other muscle relaxants, the onset of block following mivacurium administration is
dose-related. It varies between 2 and4 min afterdoses ofmivacurium varying from 0.1 to
0.25 mg/kg [30, 33]. These times are similar to those observed after equipotent doses of
atracurium but longer than the onset time of succinylcholine. The duration of clinical
relaxation is 15-20 min following doses of0.1 to 0.2 mg/kg with complete spontaneous
recovery taking up to 30 min with a dose of0.2 mg/kg [30, 33]. The duration ofaction is
also dose-related, although notas marked as observed with other neuromuscular blocking
agents. The duration ofaction is roughly halfthat ofatracurium and vecuronium and 2 to
3 times that ofsuccinylcholine [34].
Although intubating conditions at 1.5 to 2 min following 0.2 mg/kg of mivacurium
were initially reported to be good, some studies have subsequently shown that the best
intubating conditions may be obtained at 2.5 to 3 min following administration of this
dose or at 2 min with a dose of 0.25 mg/kg [33, 35]. As mivacurium is metabolised by
plasma cholinesterase, it has been suggested that antagonism of residual block is rarely
required [30]. However, ifrequired, neostigmine or edrophonium can be administered to
get a more rapid recovery [35]. It is believed that there is an inverse relationship between
plasma cholinesterase activity and the duration of mivacurium block. Moreover, depen-
dence of the agent on plasma cholinesterase for metabolism can result in prolonged neu-
romuscular block in patients with abnormal enzymes [36-38].
Because ofa shorter duration ofaction it is more convenient to administer mivacuri-
um as a continuous infusion for surgery which is longer than a few minutes. The dose of
mivacurium necessary for maintaining a 90 to 95% block is 4-8 jg/kg/min, depending
upon the anesthetic used [35, 39,40].
Mivacurium has been found to consist of a mixture of three stereoisomers, the
equipotent and most active cis-trans and trans-trans isomers as well as the markedly less
active cis-cis isomer. It is believed that the last of these isomers contributes little to the
neuromuscular blocking effect of mivacurium. The rate of clearance of mivacurium is
very high at 12.2 L/kg/hr and this is consistent with its short duration of action. The
elimination half-life ofthe two active isomers has been given as 2.1 and 2.3 min, respec-
tively, with very high rates of clearance of 4.2 and 8.3 L1kg/hr [41, 42]. Mivacurium is
associated with a prolonged half-life and prolonged duration of action in patients with
liver disease as well as in patients with renal disease, although not to the same extent as
other relaxants [43, 44]. The effects are believed to be mainly due to reduction in plasma
cholinesterase activity.
Although mivacurium is associated with good cardiovascular stability when used in
doses ofup to 0.15 mg/kg, doses higher than this may cause a transient decrease in arteri-
al pressure due to histamine liberation, an effect which can be reduced by slow adminis-
tration of the drug [45]. Similar changes have been observed using more detailed hemo-
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dynamic monitoring in patients undergoing coronary artery surgery [46].
In summary, therefore, mivacurium appears to be an agent with a shorter duration of
action although not as short as that ofsuuccinylcholine but with an onsetofaction which
is similar to that of other intermediate acting agents. The drug may be, therefore, useful
foroutpatient surgery when there is no need forrapid tracheal intubation. The usual clini-
cal initial dose is 0.15-0.2 mg/kg.
Rocuronium (ORG9426)
Rocuronium is a desacetoxy derivative of vecuronium and is a monoquaternary
steroidal neuromuscular blocking agent. The potency, in terms ofED95 is approximately
300 g±g/kg making it a relatively low potency compound [47, 48]. This low potency is a
deliberate design feature of the drug which is believed to result in a more rapid onset of
effect as it provides for delivery of more molecules of the drug to the neuromuscular
junction [49]. Doses of approximately 2 x ED95 (0.6 mg/kg) have been reported to pro-
duce maximum block in about 1.5 min with a duration ofaction which is similar to that
ofvecuronium and takes about30 min forrecoveryofTi to25% [50]. Doses greater than
this and in the region of 0.9 mg/kg have been reported to produce complete block in
about 45 sec, with a duration ofclinical relaxation of45-50 min [51]. The rapid onset of
block is associated with provision ofgood to excellent intubating conditions within 60 to
90 sec [50]. The conditions are not significantly different when compared with suxam-
ethonium [50]. Thereversibility ofthe agenthasbeen described tobe easy [47].
With arapid onset ofeffectand aduration ofaction similar to thatofvecuronium the
agent has been found to be useful for use by continuous infusion [52]. The required dose
by infusion is approximately 10gg/kg/min.
Routine cardiovascular measurements carried out in the course of neuromuscular
block have suggested no significantcardiovasculareffects with doses of0.5 to 0.6 mg/kg
[51]. Previous studies in dogs have suggested that doses of greater than 5 x ED95 may
increase the heart rate significantly [53]. A more recent detailed cardiovascular study
comparing vecuronium and rocuronium in equipotent doses (2 x ED95) in patients under-
going coronary artery bypass surgery under high dose fentanyl anesthesia have shown an
increase of 1 to 7% in heart rate with the use ofrocuronium and a similar change in the
other direction with vecuronium [54]. These workers also showed a small but statistically
significant increase in cardiac index with the use of0.6 mg/kg rocuronium. All the car-
diovascularchanges however are within acceptableclinical limits. The agenthas notbeen
shown to have any significant histamine liberating effect with doses of up to 4 x ED95
[55].
The elimination half-life of rocuronium has been observed to be approximately 97
min. in normal patients, with a slight but insignificant increase in patients with renal fail-
ure who however showed areducedclearance andan increased mean residence time [56].
This is also associated with a greater variability of clinical relaxation in patients with
renal disease. A more marked prolongation of the effect has been reported in patients
with liver disease [57]. Rocuronium would, therefore, appear to be an agent with a dura-
tion of action similar to that of vecuronium but with an onset which is much more rapid
and closer to that of succinylcholine. As a result, the intubating conditions with its use
have been described to be similar to those ofsuccinylcholine. Thedrug is still undergoing
clinical evaluation and is not yet licensed for general use. The clinical dose is likely to be
0.6 mg/kg.
The main neuromuscularfeatures ofthese agents are summarised in Table 1.
In summary, the anesthesiologist now has the long and the intermediate duration
relaxants which are relatively free from side effects [58]. We now have a fast acting non-
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Table 1. Main neuromuscular features of the new relaxants in comparison to pancuronium,
atracurium and vecuronium.
Onset time Duration
ofthe ofclinical
ED50 Intubating intubating relaxation
(.ug/kg) dose (mg/kg) dose (min) (min)
Doxacurium 30 0.03-0.05 5-10 50-150
Pipecuronium 45 0.05-0.07 4- 7 45-100
Mivacurium 70 0.15-0.2 2- 4 15- 20
Rocuronium 300 0.5- 0.6 1- 2 25- 35
Pancuronium 60 0.08-0.1 3- 5 50-100
Atracurium 225 0.4- 0.5 2- 4 25- 35
Vecuronium 40 0.08-0.1 2- 4 25- 35
The variability in the onset times and the duration of clinical relaxation is greater in agents which
are slower in onsetand longer acting.
depolarizing relaxant and a relatively shorter acting nondepolarizing relaxant but not the
one which has both these properties.
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